AAM
SRPT icon

Azzad Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Azzad Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,466
Closed -$235K – 383
2022
Q3 		$235K Hold
1,466
– – 0.02% 388
2022
Q2 		$235K Buy
+1,466
New +$108K 0.02% 381
2020
Q3 		– Sell
-1,466
Closed -$235K – 317
2020
Q2 		$235K Buy
+1,466
New +$199K 0.06% 284
2020
Q1 		– Sell
-2,932
Closed -$424K – 344
2019
Q4 		$424K Hold
2,932
– – 0.05% 312
2019
Q3 		$345K Buy
2,932
+1,468
+100% +$173K 0.04% 324
2019
Q2 		$222K Buy
+1,464
New +$178K 0.06% 286

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Azzad Asset Management's SRPT Position: Q4 2022 in Review

Azzad Asset Management sold out of Sarepta Therapeutics (SRPT) in Q4 2022, closing a stake of 1,466 shares — an estimated $235K sold.

Azzad Asset Management first reported a position in SRPT in Q2 2019 and held it in 6 quarters. The position peaked at $424K in Q4 2019. 411 funds tracked by Wall St. Rank hold SRPT as of Q4 2022.

  • Azzad Asset Management reported no remaining Sarepta Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Azzad Asset Management sold 1,466 Sarepta Therapeutics shares in Q4 2022, an estimated $235K.
  • Azzad Asset Management first reported a position in Sarepta Therapeutics in Q2 2019 and held it in 6 quarters.
  • Azzad Asset Management's Sarepta Therapeutics position peaked at $424K in Q4 2019.
  • 411 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2022.

Based on Azzad Asset Management's 13F filing for Q4 2022, filed 1 Apr 2024.